Xeris Biopharma Holdings (XERS) Enterprise Value (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Enterprise Value came in at -$111.8 million in Q1 2026, down 91.22% YoY from -$1.3 billion in Q1 2025, and down 0.64% on a QoQ basis from -$111.0 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Enterprise Value (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Enterprise Value data on file, last reported at -$111.8 million in Q1 2026.
- Quarterly Enterprise Value fell 91.22% year-over-year to -$111.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$111.8 million (down 91.22% YoY) and the FY2025 annual result came in at -$111.0 million, down 55.04% from the prior year.
- Enterprise Value declined to -$111.8 million in Q1 2026, from -$111.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$58.4 million in Q1 2025 to a low of -$132.1 million in Q1 2022.
- A 5-year average of -$88.9 million and a median of -$87.4 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 40.6% — and 2026, when it tumbled 91.22%.
- Tracing XERS's Enterprise Value over 5 years: stood at -$122.0 million in 2022, then surged by 40.6% to -$72.5 million in 2023, then rose by 1.15% to -$71.6 million in 2024, then sank by 55.04% to -$111.0 million in 2025, then decreased by 0.64% to -$111.8 million in 2026.
- The last three Enterprise Value figures came in at -$111.8 million (Q1 2026), -$111.0 million (Q4 2025), and -$91.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -882.82 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -3.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -5.79 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -2.66 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -389.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | -164.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | -121.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -121.75 Mn |
| Mar 31, 2026 | -111.75 Mn |
| Dec 31, 2025 | -111.04 Mn |
| Sep 30, 2025 | -91.60 Mn |
| Jun 30, 2025 | -59.29 Mn |
| Mar 31, 2025 | -58.44 Mn |
| Dec 31, 2024 | -71.62 Mn |
| Sep 30, 2024 | -69.40 Mn |
| Jun 30, 2024 | -77.57 Mn |
| Mar 31, 2024 | -87.35 Mn |
| Dec 31, 2023 | -72.45 Mn |
| Sep 30, 2023 | -65.98 Mn |
| Jun 30, 2023 | -80.67 Mn |
| Mar 31, 2023 | -95.10 Mn |
| Dec 31, 2022 | -121.97 Mn |
| Sep 30, 2022 | -93.43 Mn |
| Jun 30, 2022 | -111.55 Mn |
| Mar 31, 2022 | -132.15 Mn |
| Dec 31, 2021 | -102.43 Mn |
| Sep 30, 2021 | -92.98 Mn |